NPPB and stroke disorder: Similar to the rE-LY trial, the ARISTOTLE biomarker sub-study confirmed that the addition of NT-proBNP to the CHADS2 and CHA2DS2-VASc models resulted in significant improvements in their discrimination performance for both TE events and cardiovascular mortality (c statistic Aristotle: stroke 0.62 to 0.65 and cardiovascular death 0.59 to 0.69).